The last response that we discussed was the concept of differentiation as outlined in Chapter 7. For this week, we will be discussing the idea of flexibility. Once again, something that IFRX has yet to understand. It seems that every week, the potential to release news, to make a statement, to do something to expand the company, IFRX goes the other way. And as such we will discuss Flexibility in this week’s installment (something the company isnt capable of apparently)
The idea of flexibility is defined in the textbook as “the ability to change direction quickly and at low cost, given unanticipated changes in the competitive situation within which a firm is operating. ” The problem that IFRX faces is an inability to maintain flexibility within their prescribed industry. Biotech is an industry that proves difficult for even the largest of firms, however the small market cap afforded to IFRX, has them chasing one or two potentials for successful drug innovation, unlike claxo smith kline, or other major drug makers. As highlighted by their most recent collapse, it appears that they need to start looking at flexibility among their research and product lines. The inability for this company to provide variance across their research limits potential; by simply allowing researchers to utilize some time and resources to examine other chemical variation may increase the functionality, and overall return of IFRX.
IFRX 